Overview

Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL

Status:
Terminated

Trial end date:
2018-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether AFM11 is safe and active in the treatment of relapsed and/or refractory Non-Hodgkin Lymphoma (NHL).

Phase:

Phase 1

Details

Lead Sponsor:

Affimed GmbH